Objective To investigate expression of Evi 1 and MDS1 Evi 1 genes in myelodysplastic syndromes (MDS) and post MDS acute myeloid leukemia (post MDS AML), and its role in pathogenesis or progression of MDS and pos...Objective To investigate expression of Evi 1 and MDS1 Evi 1 genes in myelodysplastic syndromes (MDS) and post MDS acute myeloid leukemia (post MDS AML), and its role in pathogenesis or progression of MDS and post MDS AML Methods Expression of Evi 1 and MDS1 Evi 1 genes was examined in 31 MDS, 11 post MDS AML, and 34 de novo AML patients by a semi quantitative reverse transcription polymerase chain reaction (RT PCR) Results Evi 1 expression was not detected in bone marrow samples of 8 normal controls, but low MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH<0 1) were detected in 3 of the 8 controls Evi 1 RNA was expressed in 1 of 8 RA, 8 of 13 RAEB and 6 of 9 RAEB T patients, and the percentage of Evi 1 expression in RAEB(T) patients was higher than that in RA (P<0 05) MDS1 Evi 1 expression was detected in 5 of 8 RA, 9 of 13 RAEB and 5 of 9 RAEB T patients, and MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH>0 1) were markedly higher than those in the controls Evi 1 expression was gradually increased in 4 of 5 RAEB T patients with transformation from MDS to AML The percentages of Evi 1 and MDS1 Evi 1 expression in post MDS AML patients were significantly (P<0 01 and P<0 05 respectively) higher than those in de novo AML The colonies of hematopoietic progenitor cells were decreased in Evi 1 and MDS1 Evi 1 positive MDS patients as compared with those in Evi 1 and MDS1 Evi 1 negative patients Conclusion Abnormal expression of the Evi 1 gene and overexpression of MDS1 Evi 1 gene may play a role in the pathogenesis or progression of MDS and post MDS AML展开更多
文摘Objective To investigate expression of Evi 1 and MDS1 Evi 1 genes in myelodysplastic syndromes (MDS) and post MDS acute myeloid leukemia (post MDS AML), and its role in pathogenesis or progression of MDS and post MDS AML Methods Expression of Evi 1 and MDS1 Evi 1 genes was examined in 31 MDS, 11 post MDS AML, and 34 de novo AML patients by a semi quantitative reverse transcription polymerase chain reaction (RT PCR) Results Evi 1 expression was not detected in bone marrow samples of 8 normal controls, but low MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH<0 1) were detected in 3 of the 8 controls Evi 1 RNA was expressed in 1 of 8 RA, 8 of 13 RAEB and 6 of 9 RAEB T patients, and the percentage of Evi 1 expression in RAEB(T) patients was higher than that in RA (P<0 05) MDS1 Evi 1 expression was detected in 5 of 8 RA, 9 of 13 RAEB and 5 of 9 RAEB T patients, and MDS1 Evi 1 expression levels (MDS1 Evi 1/GAPDH>0 1) were markedly higher than those in the controls Evi 1 expression was gradually increased in 4 of 5 RAEB T patients with transformation from MDS to AML The percentages of Evi 1 and MDS1 Evi 1 expression in post MDS AML patients were significantly (P<0 01 and P<0 05 respectively) higher than those in de novo AML The colonies of hematopoietic progenitor cells were decreased in Evi 1 and MDS1 Evi 1 positive MDS patients as compared with those in Evi 1 and MDS1 Evi 1 negative patients Conclusion Abnormal expression of the Evi 1 gene and overexpression of MDS1 Evi 1 gene may play a role in the pathogenesis or progression of MDS and post MDS AML
